<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34583690</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>15</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1477-7525</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Sep</Month><Day>28</Day></PubDate></JournalIssue><Title>Health and quality of life outcomes</Title><ISOAbbreviation>Health Qual Life Outcomes</ISOAbbreviation></Journal><ArticleTitle>Design, validation and implementation of the post-acute (long) COVID-19 quality of life (PAC-19QoL) instrument.</ArticleTitle><Pagination><StartPage>229</StartPage><MedlinePgn>229</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">229</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12955-021-01862-1</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The novel coronavirus (SARS-CoV-2) has led to a global pandemic, resulting in a disease termed COVID-19, which commonly presents in adults as a typical infection of the upper respiratory tract. Although the disease is often acute, one in ten patients can continue to be affected for weeks or months, resulting in a state called long COVID. Existing evidence suggests there are no patient-centred instruments for capturing the impact of long COVID on the quality of life of people affected.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The Jandhyala Method was used to identify indicators of long COVID quality of life. The resulting post-acute (long) COVID-19 Quality of Life (PAC-19QoL) instrument was validated with a control group of unaffected participants and finally implemented in the dedicated patient registry, PAC-19QoLReg.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">15 participants suffering from long COVID, who have been positively diagnosed with COVID-19, either via diagnostic or antibody tests and a validation control group of 16 healthy participants who have not suffered from COVID-19.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Indicators submitted by participants with long COVID that address the specific impact of the illness on their quality of life.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Forty-four Quality of Life Indicators (QoLI) across four domains, namely, psychological, physical, social, and work, were agreed by the participants with long COVID to be relevant for the assessment of their quality of life (CI&#x2009;&gt;&#x2009;0.5). The validation stage identified 35/44 QoLIs that differentiated between the two groups, with a statistically significant difference between the mean QoLI Likert Scores (p&#x2009;&lt;&#x2009;0.05).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The PAC-19QoL instrument and PAC-19QoLReg prospective observational cohort clinical study will enable an understanding of disease progression, on and off treatment, on the quality of life of patients with long COVID beyond simple symptomatology.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">ClinicalTrials.gov Identifier NCT04586413; 14th October 2020.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jandhyala</LastName><ForeName>Ravi</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-7241-7476</Identifier><AffiliationInfo><Affiliation>Medialis Ltd, 13 Horse Fair, Banbury, OX16 0AH, UK. ravi@medialis.co.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Life Science and Medicine, Centre for Pharmaceutical Medicine Research, Institute of Pharmaceutical Science, King's College London, Franklin Wilkins Building,&#x202f;150 Stamford Street, London, SE1 9NH, UK. ravi@medialis.co.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04586413</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Health Qual Life Outcomes</MedlineTA><NlmUniqueID>101153626</NlmUniqueID><ISSNLinking>1477-7525</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Public health</Keyword><Keyword MajorTopicYN="N">Quality of life</Keyword><Keyword MajorTopicYN="N">Research methods</Keyword><Keyword MajorTopicYN="N">Statistics</Keyword></KeywordList><CoiStatement>The author is a visiting senior lecturer at the Centre for Pharmaceutical Medicine Research at King&#x2019;s College London responsible for research into real-world evidence approaches. The author is also the Founder and CEO of Medialis Ltd, a medical affairs consultancy and contract research organisation involved in the design and delivery of real-world evidence including the patient reported outcomes and patient registries.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>2</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>29</Day><Hour>5</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>9</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34583690</ArticleId><ArticleId IdType="pmc">PMC8477362</ArticleId><ArticleId IdType="doi">10.1186/s12955-021-01862-1</ArticleId><ArticleId IdType="pii">10.1186/s12955-021-01862-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cao X. COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol. 2020;20:269&#x2013;270. doi: 10.1038/s41577-020-0308-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0308-3</ArticleId><ArticleId IdType="pmc">PMC7143200</ArticleId><ArticleId IdType="pubmed">32273594</ArticleId></ArticleIdList></Reference><Reference><Citation>Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020;91:157&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7569573</ArticleId><ArticleId IdType="pubmed">32191675</ArticleId></ArticleIdList></Reference><Reference><Citation>Velavan TP, Meyer CG. The COVID-19 epidemic. Trop Med Int Health. 2020;25:278&#x2013;280. doi: 10.1111/tmi.13383.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/tmi.13383</ArticleId><ArticleId IdType="pmc">PMC7169770</ArticleId><ArticleId IdType="pubmed">32052514</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Wang Y, Ye D, Liu Q. Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence. Int J Antimicrob Agents. 2020;55:105948&#x2013;105948. doi: 10.1016/j.ijantimicag.2020.105948.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2020.105948</ArticleId><ArticleId IdType="pmc">PMC7156162</ArticleId><ArticleId IdType="pubmed">32201353</ArticleId></ArticleIdList></Reference><Reference><Citation>Meeting the challenge of long COVID. Nat Med 2020;26:1803. https://www.nature.com/articles/s41591-020-01177-6</Citation><ArticleIdList><ArticleId IdType="pubmed">33288947</ArticleId></ArticleIdList></Reference><Reference><Citation>Klok FA, Boon GJAM, Barco S, Endres M, Geelhoed JJM, Knauss S, Rezek SA, Spruit MA, Vehreschild J, Siegerink B. The post-COVID-19 functional status scale: a tool to measure functional status over time after COVID-19. Eur Respir J. 2020;56:2001494. doi: 10.1183/13993003.01494-2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.01494-2020</ArticleId><ArticleId IdType="pmc">PMC7236834</ArticleId><ArticleId IdType="pubmed">32398306</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee D. The COVID-19 outbreak: crucial role the psychiatrists can play. Asian J Psychiatr. 2020;50:102014&#x2013;102014. doi: 10.1016/j.ajp.2020.102014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajp.2020.102014</ArticleId><ArticleId IdType="pmc">PMC7270773</ArticleId><ArticleId IdType="pubmed">32240958</ArticleId></ArticleIdList></Reference><Reference><Citation>Bryson WJ. Long-term health-related quality of life concerns related to the COVID-19 pandemic: a call to action. Qual Life Res. 2020;30:643&#x2013;645. doi: 10.1007/s11136-020-02677-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11136-020-02677-1</ArticleId><ArticleId IdType="pmc">PMC7568937</ArticleId><ArticleId IdType="pubmed">33073307</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbon LM, GrayBuck KE, Buck LI, Huang K-N, Penumarthy NL, Wu S, Curtis JR. Development and implementation of a clinician-facing prognostic communication tool for patients with COVID-19 and critical illness. J Pain Symptom Manag. 2020;60:e1&#x2013;e6. doi: 10.1016/j.jpainsymman.2020.05.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpainsymman.2020.05.005</ArticleId><ArticleId IdType="pmc">PMC7207118</ArticleId><ArticleId IdType="pubmed">32437944</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill CL, Baird WO, Walters SJ. Quality of life in children and adolescents with Osteogenesis Imperfecta: a qualitative interview based study. Health Qual Life Outcomes. 2014;12:54. doi: 10.1186/1477-7525-12-54.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1477-7525-12-54</ArticleId><ArticleId IdType="pmc">PMC3996106</ArticleId><ArticleId IdType="pubmed">24742068</ArticleId></ArticleIdList></Reference><Reference><Citation>Guyatt GH, King DR, Feeny DH, Stubbing D, Goldstein RS. Generic and specific measurement of health-related quality of life in a clinical trial of respiratory rehabilitation. J Clin Epidemiol. 1999;52:187&#x2013;192. doi: 10.1016/S0895-4356(98)00157-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0895-4356(98)00157-7</ArticleId><ArticleId IdType="pubmed">10210235</ArticleId></ArticleIdList></Reference><Reference><Citation>Jandhyala R. Neutral theory: a conceptual framework for construct measurement in clinical research. (Pre-print) 2020. doi: 10.13140/RG.2.2.33212.16008.</Citation></Reference><Reference><Citation>Jandhyala R. Neutral theory: applicability and neutrality of using generic health-related quality of life tools in diseases or conditions where specific tools are available. BMC Med Res Methodol. 2021;21:86. doi: 10.1186/s12874-021-01279-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12874-021-01279-w</ArticleId><ArticleId IdType="pmc">PMC8077839</ArticleId><ArticleId IdType="pubmed">33902436</ArticleId></ArticleIdList></Reference><Reference><Citation>Jandhyala R. Comment on: &#x201c;Patient registries: an underused resource for medicines evaluation: operational proposals for increasing the use of patient registries in regulatory assessments&#x201d;. Drug Saf. 2019;42:1515&#x2013;1516. doi: 10.1007/s40264-019-00862-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-019-00862-x</ArticleId><ArticleId IdType="pubmed">31552605</ArticleId></ArticleIdList></Reference><Reference><Citation>Jandhyala R. A novel method for observing proportional group awareness and consensus of items arising from list-generating questioning. Curr Med Res Opin. 2020;36:883&#x2013;893. doi: 10.1080/03007995.2020.1734920.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03007995.2020.1734920</ArticleId><ArticleId IdType="pubmed">32098506</ArticleId></ArticleIdList></Reference><Reference><Citation>Jandhyala R. Delphi, non-RAND modified Delphi, RAND/UCLA appropriateness method and a novel group awareness and consensus methodology for consensus measurement: a systematic literature review. Curr Med Res. 2020;36:1873&#x2013;1887. doi: 10.1080/03007995.2020.1816946.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03007995.2020.1816946</ArticleId><ArticleId IdType="pubmed">32866051</ArticleId></ArticleIdList></Reference><Reference><Citation>Khandkar SH. Open coding. Univ Calg. 2009;23:2009.</Citation></Reference><Reference><Citation>Stemler S. An overview of content analysis. Pract Assess Res Eval. 2000;7:17.</Citation></Reference><Reference><Citation>Arribas F, Ormaetxe JM, Peinado R, Perulero N, Ram&#xed;rez P, Badia X. Validation of the AF-QoL, a disease-specific quality of life questionnaire for patients with atrial fibrillation. EP Europace. 2010;12:364&#x2013;370. doi: 10.1093/europace/eup421.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/europace/eup421</ArticleId><ArticleId IdType="pubmed">20056594</ArticleId></ArticleIdList></Reference><Reference><Citation>Dwivedi RC, Rose SS, Roe JWG, Khan AS, Pepper C, Nutting CM, Clarke PM, Kerawala CJ, Rhys-Evans PH, Harrington KJ, Kazi R. Validation of the Sydney Swallow Questionnaire (SSQ) in a cohort of head and neck cancer patients. Oral Oncol. 2010;46:e10&#x2013;e14. doi: 10.1016/j.oraloncology.2010.02.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.oraloncology.2010.02.004</ArticleId><ArticleId IdType="pubmed">20219415</ArticleId></ArticleIdList></Reference><Reference><Citation>Marquis P, Fayol C, Joire JE. Clinical validation of a quality of life questionnaire in angina pectoris patients. Eur Heart J. 1995;16:1554&#x2013;1560. doi: 10.1093/oxfordjournals.eurheartj.a060777.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oxfordjournals.eurheartj.a060777</ArticleId><ArticleId IdType="pubmed">8881847</ArticleId></ArticleIdList></Reference><Reference><Citation>Tubert-Jeannin S, Riordan PJ, Morel-Papernot A, Porcheray S, Saby-Collet S. Validation of an oral health quality of life index (GOHAI) in France. Commun Dent Oral Epidemiol. 2003;31:275&#x2013;284. doi: 10.1034/j.1600-0528.2003.t01-1-00006.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1034/j.1600-0528.2003.t01-1-00006.x</ArticleId><ArticleId IdType="pubmed">12846850</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S, Wang Y, Xue J, Zhao N, Zhu T. The impact of COVID-19 epidemic declaration on psychological consequences: a study on active Weibo users. Int J Environ Res Public Health. 2020;17:2032. doi: 10.3390/ijerph17062032.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph17062032</ArticleId><ArticleId IdType="pmc">PMC7143846</ArticleId><ArticleId IdType="pubmed">32204411</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheehy LM. Considerations for postacute rehabilitation for survivors of COVID-19. JMIR Public Health Surveill. 2020;6:e19462. doi: 10.2196/19462.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/19462</ArticleId><ArticleId IdType="pmc">PMC7212817</ArticleId><ArticleId IdType="pubmed">32369030</ArticleId></ArticleIdList></Reference><Reference><Citation>Menni C, Valdes AM, Freidin MB, Sudre CH, Nguyen LH, Drew DA, Ganesh S, Varsavsky T, Cardoso MJ, El-Sayed Moustafa JS, et al. Real-time tracking of self-reported symptoms to predict potential COVID-19. Nat Med. 2020;26:1037&#x2013;1040. doi: 10.1038/s41591-020-0916-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0916-2</ArticleId><ArticleId IdType="pmc">PMC7751267</ArticleId><ArticleId IdType="pubmed">32393804</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs LG, Gourna Paleoudis E, Lesky-Di Bari D, Nyirenda T, Friedman T, Gupta A, Rasouli L, Zetkulic M, Balani B, Ogedegbe C. Persistence of symptoms and quality of life at 35 days after hospitalization for COVID-19 infection. PLoS ONE. 2020;15:e0243882. doi: 10.1371/journal.pone.0243882.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0243882</ArticleId><ArticleId IdType="pmc">PMC7732078</ArticleId><ArticleId IdType="pubmed">33306721</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>